We found that SH3TC2 was significantly overexpressed in 7 cancers, including bladder urothelial cancer (BLCA), cholangio cancer (CHOL), colon adenocarcinoma (COAD), acute myeloid leukemia (LAML), pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), and skin cutaneous melanoma (SKCM), while downregulated in 2 cancers, breast invasive carcinoma (BRCA), and testicular germ cell tumors (TGCT), compared with the corresponding normal tissue samples (Figures 1(a)–1(i)). Here, SH3TC2 is linked to cutaneous melanoma.